PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29767555-8	2018	Mechanistically, JQ1 suppressed cisplatin-induced phosphorylation or activation of p53 and Chk2, key events in DNA damage response.	Cisplatin	32-41	checkpoint kinase 2	Mus musculus	91-95	
23211021-0	2012	Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.	Cisplatin	83-92	checkpoint kinase 2	Mus musculus	37-41	
24853623-6	2014	Therefore, the selective targeting of Chk1 and Chk2 by oncolytic adenovirus mutants was chosen to treat resistant tumor xenograft mice, and the maximum antitumoral efficacy was achieved with the combined co-abrogation of Chk1 and Chk2 in the presence of low-dose cisplatin.	Cisplatin	263-272	checkpoint kinase 2	Mus musculus	47-51	
24853623-6	2014	Therefore, the selective targeting of Chk1 and Chk2 by oncolytic adenovirus mutants was chosen to treat resistant tumor xenograft mice, and the maximum antitumoral efficacy was achieved with the combined co-abrogation of Chk1 and Chk2 in the presence of low-dose cisplatin.	Cisplatin	263-272	checkpoint kinase 2	Mus musculus	230-234	
23211021-10	2012	Combination of CDDP with serum starvation in vitro increased the activation of ATM/Chk2/p53 signaling pathway compared to either treatment alone resulting in an enhanced sensitization of cancer cells to CDDP.	Cisplatin	15-19	checkpoint kinase 2	Mus musculus	83-87	
23211021-10	2012	Combination of CDDP with serum starvation in vitro increased the activation of ATM/Chk2/p53 signaling pathway compared to either treatment alone resulting in an enhanced sensitization of cancer cells to CDDP.	Cisplatin	203-207	checkpoint kinase 2	Mus musculus	83-87	
20700484-5	2010	Moreover, this combination treatment results in higher Chk1 and Chk2 kinase activity than does treatment with cisplatin alone and can activate Chk2 in pleural metastases tumor xenograft in mice.	Cisplatin	110-119	checkpoint kinase 2	Mus musculus	64-68	
22159226-0	2012	Orphan receptor TR3 participates in cisplatin-induced apoptosis via Chk2 phosphorylation to repress intestinal tumorigenesis.	Cisplatin	36-45	checkpoint kinase 2	Mus musculus	68-72	
22159226-2	2012	Here, we demonstrate that cisplatin effectively induces orphan nuclear receptor TR3 phosphorylation by activating Chk2 kinase activity and promoting cross talk between these two proteins, thereby contributing to the repression of intestinal tumorigenesis via apoptosis.	Cisplatin	26-35	checkpoint kinase 2	Mus musculus	114-118	
22159226-8	2012	Taken together, our study reveals a novel cross talk between Chk2 and TR3 and sheds light on the mechanism of cisplatin-induced apoptosis through TR3.	Cisplatin	110-119	checkpoint kinase 2	Mus musculus	61-65	
20700484-5	2010	Moreover, this combination treatment results in higher Chk1 and Chk2 kinase activity than does treatment with cisplatin alone and can activate Chk2 in pleural metastases tumor xenograft in mice.	Cisplatin	110-119	checkpoint kinase 2	Mus musculus	143-147	
18162465-0	2008	ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.	Cisplatin	68-77	checkpoint kinase 2	Mus musculus	4-8	
18162465-9	2008	Downstream of ATR, both Chk1 and Chk2 are phosphorylated during cisplatin treatment in an ATR-dependent manner.	Cisplatin	64-73	checkpoint kinase 2	Mus musculus	33-37	
18162465-11	2008	Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis.	Cisplatin	79-88	checkpoint kinase 2	Mus musculus	14-18	
18162465-12	2008	In vivo in C57BL/6 mice, ATR and Chk2 are activated in renal tissues following cisplatin treatment.	Cisplatin	79-88	checkpoint kinase 2	Mus musculus	33-37	
18162465-13	2008	Together, the results suggest an important role for the DNA damage response mediated by ATR-Chk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.	Cisplatin	147-156	checkpoint kinase 2	Mus musculus	92-96